A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
by on Monday, March 26th, 2012 | No Comments
Conditions: KRAS Mutated Colorectal Adenocarcinoma.; Metastatic Pancreatic Adenocarcinoma; BRAF Mutated Melanoma
Intervention: Drug: MEK 162 + AMG 479
Sponsor: Novartis Pharmaceuticals
Not yet recruiting – verified March 2012
Read the rest here: A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors